Open an account

Zoetis

ZTS · NYSE

$80.04+$0.45 (+0.57%)TodayMarket closed ·
Prev close $79.59

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Employees
14,500
Headquarters
Parsippany, New Jersey
Listed
Feb 1, 2013
Sector
Health Care
Industry
Pharmaceuticals
Website
zoetis.com

ZTS key statistics

Market cap
31.87B
Price-earnings ratio
13.11
Dividend yield
2.71%
Average volume
4.16M
Volume
2.45M
Open price
$79.64
High today
$80.25
Low today
$79.03
52 Week high
$148.30
52 Week low
$68.77

Zoetis (ZTS) at a glance

Zoetis (ZTS) last traded at $80.04, with a market cap of 31.87B, a price-to-earnings ratio of 13.11 and a dividend yield of 2.71%.

Today the stock has traded between $79.03 and $80.25. The current price is 1.3% above the day's low and 0.3% below its high.

Volume so far is 2.45M shares, below the average of 4.16M shares a day.

Over the past year Zoetis has ranged from $68.77 to $148.30, and now sits 14% of the way up that range.

Zoetis met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $1.87 per share against an estimate of $1.87.

The average analyst price target is $101.29, 26.5% above the current price, from 17 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

41%of 17 analyst ratings say Buy
  • Buy41.2%
  • Hold58.8%
  • Sell0.0%
Price target · 17 analystsAvg $101.29
Low
$80.80
Now
$80.04
High
$168.00

ZTS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 5.4% on average.

  1. Q3 FY24: reported $1.58 per share against an estimate of $1.47
  2. Q4 FY24: reported $1.40 per share against an estimate of $1.35
  3. Q1 FY25: reported $1.48 per share against an estimate of $1.41
  4. Q2 FY25: reported $1.76 per share against an estimate of $1.63
  5. Q3 FY25: reported $1.70 per share against an estimate of $1.64
  6. Q4 FY25: reported $1.48 per share against an estimate of $1.42
  7. Q1 FY26: reported $1.53 per share against an estimate of $1.63
  8. Q2 FY26: reported $1.87 per share against an estimate of $1.87

ZTS news

  • Press releaseBusiness Wire

    Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

  • Press releaseBusiness Wire

    Zoetis Appoints Iris Knobloch to its Board of Directors

  • Press releaseBusiness Wire

    Zoetis Declares Fourth Quarter 2026 Dividend

  • Press releaseBusiness Wire

    New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

  • Press releaseBusiness Wire

    Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releaseBusiness Wire

    Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

  • FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies

Similar companies

Companies in the same industry as Zoetis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.